ILE Isolagen

EXTON, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) announced today the engagement of the Trout Group to provide institutional investor relations services to the Company. The Trout Group provides investor relations and strategic advisory services solely to the life sciences industry and has a global reach with offices in New York, San Francisco and Boston. Over the years, the Trout Group has developed a network of institutional relationships with analysts, portfolio managers, investment bankers and venture capitalists in the US biotechnology community. "Our collaboration with the Trout Group is part of our corporate strategy to expand the Company's shareholder base and to continue to tell the story of Isolagen to the institutional investor community," said Susan Ciallella, Chief Executive Officer of Isolagen. ABOUT ISOLAGEN, INC. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and actual results may differ materially from the forward-looking statements. Isolagen, Inc. does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein. DATASOURCE: Isolagen, Inc. CONTACT: Lee M. Stern, x22, or Marcy Strickler, x27, both of The Trout Group, +1-212-477-9007, for Isolagen, Inc. Web site: http://www.isolagen.com/

Copyright